June / July, 2016
Partager Partager Partager Partager

Within the framework of a competitive process in favor of SMEs and novel ideas, the Worldwide Innovation Challenge selects company projects presenting major innovations and answering one of the eight Goals* described in the report “One Principle and Seven Goals for Innovation” and its addendum. To select the best projects for the French economy in line with the objectives of the action financed under the “Invest for the Future” program, the Worldwide Innovation Challenge takes place in 3 phases.
CMI 2030
After the first Start-up Phase in 2014, 110 high-potential projects were selected among which 7 Genopole companies. In 2015, a second phase – Risk Reduction Phase – led to the selection of 35 projects. To leverage these achievements, a new Start-up phase has been set up, based on 8 Goals, including “Personalized Medicine”. Within this goal, only 16 of the 89 applications were selected, 3 of which are Genopole companies: Traaser, Endodiag and Ap Advance. Two other Genopole companies, Acticor Biotech and Pili Biotech were also selected, respectively for “Silver Economy” and “Plant-based Chemistry”.

* Energy Storage, Recycling of Metals, Development of Marine Resources, Plant-based Proteins and Plant-based Chemistry, Personalized Medicine, Silver Economy, Innovation in the Service of Longevity, Promoting Big Data
Read more {...} read more

Algama and Global Bioenergies – Still Going Strong

The young French foodtech company, Algama, which we introduced in our March edition, has raised €3.5 million in new funding just two years after its creation to grow its business in France and abroad, with Hong Kong fund Horizons Ventures becoming a reference shareholder in the start-up along with French investors.The funds raised will enable Algama to scale up the R&D work at its FoodLab in Genopole and to attract new talent while extending its global operations.
Algama's business development activities are now being conducted not only in Paris but also (since March 2016) in New York.
Thanks to these funds, Algama will be able to strengthen its partnerships and consolidate its leading position in the field of microalgae development.
Read more {...} read more
Global Bioenergies

Also continuing its development, Global Bioenergies – one of the few companies worldwide, and the only one in Europe to develop a process to convert renewable resources into hydrocarbons through fermentation – along with IBN-One, Cristal Union and L’Oréal announced the launch early June of a 44-month industrial and commercial project focused on the first bio-isobutene plant.
The Investissements d’Avenir programme is providing a 9-million euro grant to Global Bioenergies and IBN-One for this programme.
As the project coordinator, Global Bioenergies will mainly be responsible for completing the industrial development of the process, receiving up to €5.7 million. Frédéric Pâques, Chief Operations Officer of Global Bioenergies, said: “The process is now entering a new phase of development: step by step, we are moving closer to our targeted performance, as we are getting ready to run the process in our demo plant, whose construction in Germany will be completed within the next few months.
Read more {...} read more


New Positive Data for Integragen

Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab. The data presented further validates previous studies which have documented that miR-31-3p expression in the primary tumor of mCRC patients is predictive of the effect of anti-EGFR therapy.
Read more {...} Lire la suite


Celebrating Achievements at Genopole

Many events were on the agenda this month among which three important annual gatherings over three days from 22 to 24 June. First and foremost, the Genoforum. This year's speaker was Jean Weissenbach, the internationally renowned geneticist who received the Médaille d'or 2008 of the CNRS, highest distinction in France for scientific research. On the following day, still at the Genocentre, was held the Journée des plates-formes where certain platforms were open to visitors for the first time. And, finally, to top off the week, the Genopole picnic brought together all the players of the campus around a friendly potluck lunch on the campus grounds.


BIO conference - Genopole

Back from BIO

The entire biotech world gathered in San Francisco for a very intense week early June. The Genopole team had about 60 business meetings over 3 days allowing them to catch up with companies and meet new ones.
They were able to exchange with major players of the pharmaceutical industry and investor funds to present some of the Genopole start-ups. BIO was also the occasion to meet with international start-ups to discuss possible business opportunities in France.

BIO is the major networking event for the biotech industry and is the perfect place to get a glimpse of where this industry is heading. We had the confirmation that we have indeed shifted into the era of precision medicine with the high recurrence of the term "targeted therapy" pronounced during the different meetings.
Furthermore, the world of finance is getting smaller with new players now participating in BIO as well.
A start-up can now meet with funds coming from all around the world with Asian and Russian funds joining the usual from USA, Canada and Western Europe.

The 2016 edition sets new record for partnering meeting and we are looking forward to the 2017 edition in San Diego.

An Agreement between Genopole and South Korean R&D Institutions

On June 2, Genopole, Osong Medical Innovation Foundation (KBIO) and Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) signed a Strategic Exploratory Agreement (SEA).
KBIO and DGMIF are non-for-profit organisations whose mission is to support development of new biotherapeutics and medicinal chemistry, as well as of high-tech and digital medical devices.
These organisations have been mandated by the South Korean government to host and support inventors and innovators with novel ideas on their state-of-the-art facilities.
The parties have engaged into formal exchanges to explore partnering initiatives between France and South Korea.

Topics of immediate relevance include

South Korean - Genopole
South Korean - KBIO
South Korean - DGMIF
a) Technology and expertise transfer from Genopole to KBIO and DGMIF on all matters relating to the development of processes to support entrepreneurs and the creation of start-ups, as well as relating to joint clinical trials conducted by the Parties in Korea and in France,
b) The development of innovative personalised and regenerative medicine and the implementation of protocols in pharmacogenetics to improve of drug delivery processes,
c) The identification of sources of financing from Korea and from France to support the establishment of joint collaborative R&D and innovation programs between the two countries,
d) Scouting of French and Korean companies that would benefit directly of the technology platforms established in Korea and France, respectively.
The agreement between the parties comes as a result of the France - South Korean Year and was signed during President Park Geun-hye's state visit to France.

  For additional information, write to